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gastric carcinoma shortly after
chemotherapy for colonic cancerWen-Chih Huang, Chien-Chen Tsai*Department of Anatomic Pathology, Far Eastern Memorial Hospital, New Taipei City, TaiwanReceived 8 April 2013; accepted 18 April 2013Occurrences of EpsteineBarr virus (EBV)-associated gastric
carcinoma (EBVaGC) are usually uncommon, and it was first
reported in 1990.1 Rapid development of a subsequent
EBVaGCafter a cancer episode is extremely rare and only one
case was previously reported.2 In this report, we present the
case of a male patient who developed EBVaGC after an
adjuvant chemotherapy for colonic cancer in 2 months.
A 69-year-old male patient presented with tarry stool
passage for 1 week. His past history was remarkable for
transverse colon adenocarcinoma status after right hemi-
colectomy. The tumor stage was T3N1M0 and he underwent
an adjuvant chemotherapy treatment 2 months before.
The carcinoembryonic antigen level was 8.0 ng/mL.
Results of a panendoscopic study revealed an ulcerative
mass at the middle body of the stomach (Fig. 1A). A
computed tomography was performed, which showed a 4-
cm ulcerative tumor at the anterior wall of gastric body
(Fig. 1B). There was no evidence of local recurrence of
colonic cancer. Results of a gastric biopsy revealed malig-
nancy and the patient received subtotal gastrectomy.
Results of histopathological findings in the stomach
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http://dx.doi.org/10.1016/j.jfma.2013.04.010nucleoli arranged in a syncytial pattern infiltrating the
abundant lymphoid background (Fig. 1C; hematoxylin and
eosin stain, 400). Immunohistochemically, the tumor cells
were positive for pan-cytokeratin. Results of EpsteineBarr
encoding region in situ hybridization were positive (Fig. 1D)
and EBVaGC was diagnosed. The patient remains stable 2
years postoperatively.
EBVaGC is uncommon and the clinical features reveal
male predominance, relatively young age compared with
EBV-negative gastric carcinoma, and frequently occurring at
the proximal stomach region.3,4 EBVaGC is associated with
higher incidence of multiple carcinomas at different sites of
the stomach and gastric remnant carcinoma status after a
partial gastrectomy for benign gastric diseases.4,5 There are
two histopathological patterns: an ordinary type of adeno-
carcinoma and a lymphoepithelioma-like carcinoma. More
than 80% of lymphoepithelioma-like carcinoma is associated
with EBV.4 Some studies have reported differences in the
survival rate between patients with EBVaGC and EBV-
negative gastric carcinoma. van Beek et al reported that
EBVaGC was associated with a lower rate of lymph node
involvement and better cancer-specific survival3; however,
other studies failed to reveal a significant relationship.
EBV is associated with the transformation of various types
of tumors, including hematologic neoplasms (NK/T cell lym-
phoma, Burkitt lymphoma, Hodgkin lymphoma, post-
transplant lymphoproliferative disorder), mesenchymal
tumor (leiomyosarcoma), and epithelial tumors (nasopha-
ryngeal carcinoma, gastric carcinoma, lymphoepithelioma-
like carcinoma).& Formosan Medical Association. All rights reserved.
Figure 1 (A) An ulcerative mass at the middle body of the stomach. (B) Results of a computed tomography showed a 4-cm ul-
cerative tumor at the anterior wall of gastric body (arrow). (C) Histological features of tumor cells arranged in a syncytial pattern
infiltrating the lymphoid background (hematoxylin and eosin stain, 400). (D) The tumor cells were positive for EpsteineBarr
encoding region in situ hybridization (100).
Subsequent EpsteineBarr virus-associated 191Our patient developed subsequent EBVaGC after an
adjuvant chemotherapy for colonic cancer in 2 months. The
interval was quite short. In the literature, only a case
report described a patient, who received hematopoietic
stem cell transplantation for the treatment of multiple
myeloma and developed EBVaGC after 3-month immuno-
suppression.2 They illustrated the possible sequences of
mucosal damage by graft versus host disease, immunosup-
pression, and EBV re-activation leading to the initiation of
carcinogenesis. To understand the actual mechanism,
further investigations of more similar cases are needed in
the future. The clinicians and pathologists should be aware
of the possibility of EBV-associated entity when the pa-
tients are in the immunocompromised status.
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